Literature DB >> 19726290

[Remifentanil preconditioning lowers cardiac troponin I levels in patients undergoing off-pump coronary artery bypass graft surgery].

Zhong-dong Xu1, Mu Jin, Wei-xiong He, Shu-xuan Xia, Yi-fan Zhao, Bo He, De-xiong Cao, Shu-ling Peng, Jue Li, Ming-hui Cao.   

Abstract

OBJECTIVE: To investigate the value of cardiac troponin I (cTnI) levels in assessing myocardial protection by remifentanil precondition against myocardial injury induced by off-pump coronary artery bypass (OPCAB).
METHODS: Twenty-four patients undergoing OPCAB were randomized into control and remifentanil preconditioning group (n=12). All the patients received pretreatment with oral diazepam (10 mg), intramuscular morphine (10 mg) and hyosine (0.3 mg). General anesthesia was induced with midazolam (0.08 mg/kg), etomidate (0.1-0.3 mg/kg), fentanyl (5-10 microg/kg), and rocuronium (1 mg/kg), and maintained with isoflurane inhalation and propofol infusion. Intermittent fentanyl and pipecuronium were given intravenously. In remifentanil preconditioning group, remifentanil (5 microg/kg in 50 ml normal saline) was infused in 10 min after anesthesia induction, and only NS was administered in the control group. Blood samples were obtained before and at 0, 2, 6, 24, and 48 h after the operation to determine serum cTnI levels.
RESULTS: In both of the two groups, the cTnI levels increased significantly at the postoperative time points (0, 2, 6, 24, and 48 h) as compared with those before the operation (P<0.05). The cTnI levels of remifentanil preconditioning group were markedly decreased after the operation in comparison with those of the control group (P<0.05).
CONCLUSION: Remifentanil preconditioning decreases the cTnI levels and reduces myocardial injury induced by OPCAB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726290

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  8 in total

Review 1.  Opioid-induced cardioprotection.

Authors:  Katsuya Tanaka; Judy R Kersten; Matthias L Riess
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 2.  [Cardioprotection in cardiac surgical patients : Everything good comes from the heart].

Authors:  C Stoppe; P Meybohm; M Coburn; A Goetzenich
Journal:  Anaesthesist       Date:  2016-03       Impact factor: 1.041

Review 3.  Opioid receptors and cardioprotection - 'opioidergic conditioning' of the heart.

Authors:  John P Headrick; Louise E See Hoe; Eugene F Du Toit; Jason N Peart
Journal:  Br J Pharmacol       Date:  2015-02-27       Impact factor: 8.739

4.  Morphine and remifentanil-induced cardioprotection: its experimental and clinical outcomes.

Authors:  Jin Mo Kim; Young Ho Jang; Jun Kim
Journal:  Korean J Anesthesiol       Date:  2011-11-23

Review 5.  Myocardial conditioning techniques in off-pump coronary artery bypass grafting.

Authors:  Marco Moscarelli; Prakash P Punjabi; Gamov I Miroslav; Paolo Del Sarto; Francesca Fiorentino; Gianni D Angelini
Journal:  J Cardiothorac Surg       Date:  2015-01-20       Impact factor: 1.637

6.  Remifentanil preconditioning protects against hypoxia-induced senescence and necroptosis in human cardiac myocytes in vitro.

Authors:  Anna Lewinska; Jagoda Adamczyk-Grochala; Dominika Bloniarz; Beata Horeczy; Slawomir Zurek; Arkadiusz Kurowicki; Bogumila Woloszczuk-Gebicka; Kazimierz Widenka; Maciej Wnuk
Journal:  Aging (Albany NY)       Date:  2020-06-25       Impact factor: 5.682

7.  Effect of the Aortic Root Infusion of Sufentanil on Ischemia-Reperfusion Injury in Patients Undergoing Coronary Artery Bypass Grafting: A Randomized Clinical Trial.

Authors:  Mohammad Bagher Khosravi; Mahdi Kahrom; Mahdi Tahari; Kambiz Alizadeh; Ghasem Soltani; Mohammad Ali Ghanad
Journal:  J Tehran Heart Cent       Date:  2019-10

Review 8.  Clinical Applicability of Conditioning Techniques in Ischemia-Reperfusion Injury: A Review of the Literature.

Authors:  Kuldeep Kumar; Nirmal Singh; Amteshwar S Jaggi; Leonid Maslov
Journal:  Curr Cardiol Rev       Date:  2021
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.